Skip to content

HISTOLOGICAL RESULTS IN TRANSGENDER INDIVIDUALS ASSIGNED TO FEMALES AT BIRTH UNDERGOING GENDER AFFIRMATION SURGERY AND IN TESTOSTERONE THERAPY

HISTOLOGICAL RESULTS IN TRANSGENDER INDIVIDUALS ASSIGNED TO FEMALES AT BIRTH UNDERGOING GENDER AFFIRMATION SURGERY AND IN TESTOSTERONE THERAPY

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06710496
Enrollment
100
Registered
2024-11-29
Start date
2024-12-31
Completion date
2025-12-31
Last updated
2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comorbidities and Coexisting Conditions, Drugs, Gender Affirmation Surgery, Gynecological Disorders, Gynecological Surgery, Hormone Replacement Therapy, Pregnancy, Smoking Behavior, Testosterone Replacement Therapy, Transgender Men

Keywords

transgender, afab, histology

Brief summary

The aim of this study is to report histological results of genital organs removed during gender affirmg surgery in transgender people assigned female at birth (AFAB), to increase the knowledge about the long-term effects of gender affirming hormone therapy with testosterone on these organs and to evaluate the incidence of benign and malign gynecological pathology in AFAB transgender people.

Detailed description

This retrospective, observational, single-center study aims to analyze histological data obtained from the analysis of ovaries, fallopian tubes, uterine body, endometrium, and cervix of assigned female at birth (AFAB) transgender individuals who underwent gender affirming surgey (GAS) with hysterectomy and bilateral adnexectomy or hysterectomy alone following the administration of exogenous Testosterone (T). Histological results of the genital organs removed during GAS can provide important information about the effects and safety of loong term T treatment on these organs. Data on this subject is scarce in the literature. For this reason, even today, pathologists have not been able to establish guidelines for describing the histological results obtained from these patients.Furthermore, this analysis will evaluate the incidence of benign and malignant gynecological pathology in AFAB transgender people.

Interventions

analysis of medical records of the patients

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* gender incongruence diagnosis * people assigned female at birth * age \>18 years * gender affirming surgery with hysterectomy * testosterone therapy

Exclusion criteria

* previous gynecological surgery * previous gynecological disorder diagnosis

Design outcomes

Primary

MeasureTime frame
histological description of genital organs6 months

Secondary

MeasureTime frame
prevalence of malignant and benign gynecological pathology6 months

Countries

Italy

Contacts

Primary ContactMaria Cristina Meriggiola, Associate Professor
segreteria.meriggiola@gmail.com+390512144391

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026